Phosphoinositide 3′-Kinase Inhibition in Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Phosphoinositide 3′-Kinase Inhibition in Chronic Lymphocytic Leukemia

Published:2013-04 Issue:2 Volume:27 Page:329-339
ISSN:0889-8588
Container-title:Hematology/Oncology Clinics of North America
language:en
Short-container-title:Hematology/Oncology Clinics of North America

Author:

Davids Matthew S.,Brown Jennifer R.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference48 articles.

1. Chronic lymphocytic leukemia;Chiorazzi;N Engl J Med,2005

2. The microenvironment in mature B-cell malignancies: a target for new treatment strategies;Burger;Blood,2009

3. Chronic lymphocytic leukemia: revelations from the B-cell receptor;Stevenson;Blood,2004

4. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia;Friedberg;Blood,2010

5. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation;Zent;Cancer,2010

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PI 3 Kinase, AKT , and m TOR Inhibitors;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

2. Molecular Structure, Spectroscopic Investigation, Docking and in Vitro Cytotoxicity Studies of 7-Methoxycoumarin as anti-Leukemia Agent;Polycyclic Aromatic Compounds;2021-10-20

3. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?;Frontiers in Immunology;2021-01-20

4. Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study;American Journal of Hematology;2020-01-16

5. Umbralisib tosylate. Phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor, Hematological cancer therapy;Drugs of the Future;2018